The results showed that the construction of 3rd generation CAR-T cells with both (4-1BB and CD28) domains was associated with even more potent anti-tumor response compared to CAR-T cells with single 4-1BB construct in mice CD19(+) leukemia and lymphoma tumor models, suggesting a synergistic role costimulation in engineering antileukemia UCB effector cells. Here, CD19 is linked to neoplasm.